Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Pingping Song
Modality
UNKNOWN
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05765877CT.gov Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05351320CT.gov WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC | — | Unknown | — | — | — |
NCT05801107CT.gov Study to Investigate the Efficacy and Safety of WX-0593 in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | — | Unknown | — | — | — |
NCT04632758CT.gov Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients | — | Unknown | — | — | — |
NCT04641754CT.gov A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03389815CT.gov A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| wx-0593 (this asset) | Pingping Song | P3 | B · 58 |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Endostatin | Henan Cancer Hospital | P4 | BBB |
| Zorifertinib | Alpha Biopharma (Jiangsu) Co., Ltd. | P2/3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Vinorelbine Ditartrate | Intergroupe Francophone de Cancerologie Thoracique | P4 | BB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. wx-0593 in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/wx-0593-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →